| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
|
Lancet
|
2013
|
3.92
|
|
2
|
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.
|
Lancet Infect Dis
|
2011
|
3.59
|
|
3
|
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
|
Int J Epidemiol
|
2011
|
2.80
|
|
4
|
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
|
PLoS Med
|
2013
|
2.49
|
|
5
|
Response to combination antiretroviral therapy: variation by age.
|
AIDS
|
2008
|
2.28
|
|
6
|
Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection.
|
Clin Infect Dis
|
2011
|
1.97
|
|
7
|
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
|
Clin Infect Dis
|
2008
|
1.82
|
|
8
|
Natural history of chronic hepatitis B in co-infected patients.
|
J Hepatol
|
2005
|
1.77
|
|
9
|
The development of artificial neural networks to predict virological response to combination HIV therapy.
|
Antivir Ther
|
2007
|
1.71
|
|
10
|
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
|
Lancet Infect Dis
|
2011
|
1.68
|
|
11
|
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis.
|
J Clin Microbiol
|
2007
|
1.60
|
|
12
|
Protura of Italy, with a key to species and their distribution.
|
Zookeys
|
2011
|
1.38
|
|
13
|
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.
|
PLoS One
|
2010
|
1.33
|
|
14
|
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
|
Artif Intell Med
|
2009
|
1.31
|
|
15
|
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.
|
Euro Surveill
|
2015
|
1.29
|
|
16
|
Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.
|
AIDS
|
2012
|
1.29
|
|
17
|
Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome.
|
J Acquir Immune Defic Syndr
|
2003
|
1.28
|
|
18
|
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.
|
PLoS One
|
2010
|
1.13
|
|
19
|
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
|
Arch Intern Med
|
2010
|
1.12
|
|
20
|
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.
|
BMC Infect Dis
|
2012
|
1.10
|
|
21
|
Increasing clinical virulence in two decades of the Italian HIV epidemic.
|
PLoS Pathog
|
2009
|
1.10
|
|
22
|
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
|
J Acquir Immune Defic Syndr
|
2012
|
1.04
|
|
23
|
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
|
J Acquir Immune Defic Syndr
|
2003
|
1.01
|
|
24
|
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.
|
J Antimicrob Chemother
|
2011
|
1.01
|
|
25
|
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
|
J Antimicrob Chemother
|
2011
|
0.97
|
|
26
|
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy).
|
BMC Public Health
|
2011
|
0.95
|
|
27
|
Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience.
|
AIDS Patient Care STDS
|
2011
|
0.95
|
|
28
|
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
|
Antivir Ther
|
2007
|
0.94
|
|
29
|
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.
|
J Infect Dis
|
2013
|
0.94
|
|
30
|
RegaDB: community-driven data management and analysis for infectious diseases.
|
Bioinformatics
|
2013
|
0.93
|
|
31
|
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
|
Antivir Ther
|
2008
|
0.93
|
|
32
|
Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.
|
HIV Clin Trials
|
2002
|
0.92
|
|
33
|
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.
|
Retrovirology
|
2014
|
0.92
|
|
34
|
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
|
Antivir Ther
|
2010
|
0.89
|
|
35
|
Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.
|
Drugs
|
2012
|
0.88
|
|
36
|
Update on epidemiology of HCV in Italy: focus on the Calabria Region.
|
BMC Infect Dis
|
2014
|
0.86
|
|
37
|
Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis.
|
J Med Virol
|
2008
|
0.86
|
|
38
|
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients.
|
J Transl Med
|
2012
|
0.86
|
|
39
|
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.
|
J Clin Lab Anal
|
2002
|
0.86
|
|
40
|
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.
|
Clin Infect Dis
|
2013
|
0.85
|
|
41
|
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.
|
J Infect Dis
|
2012
|
0.84
|
|
42
|
Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).
|
J Acquir Immune Defic Syndr
|
2004
|
0.84
|
|
43
|
Screening and Management of HIV-2-Infected Individuals in Northern Italy.
|
AIDS Patient Care STDS
|
2008
|
0.84
|
|
44
|
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy.
|
Antivir Ther
|
2006
|
0.84
|
|
45
|
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2002
|
0.84
|
|
46
|
No evidence of benefical effect of GB virus type C infection on the course of HIV infection.
|
AIDS
|
2002
|
0.84
|
|
47
|
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
|
Antivir Ther
|
2008
|
0.83
|
|
48
|
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target?
|
Intervirology
|
2004
|
0.82
|
|
49
|
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received.
|
AIDS Res Ther
|
2012
|
0.82
|
|
50
|
Genotyping for guiding drug choice in human immunodeficiency virus-infected children failing multiple antiretroviral treatment regimens.
|
Pediatr Infect Dis J
|
2005
|
0.82
|
|
51
|
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response.
|
PLoS One
|
2013
|
0.82
|
|
52
|
Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance.
|
Clin Dev Immunol
|
2012
|
0.82
|
|
53
|
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.
|
J Acquir Immune Defic Syndr
|
2015
|
0.82
|
|
54
|
The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
|
J Acquir Immune Defic Syndr
|
2009
|
0.82
|
|
55
|
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.
|
J Acquir Immune Defic Syndr
|
2012
|
0.81
|
|
56
|
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.
|
AIDS Patient Care STDS
|
2007
|
0.81
|
|
57
|
SENV infection in HIV-positive patients: prevalence, subtype characterization, and impact on HIV disease progression.
|
AIDS Res Hum Retroviruses
|
2003
|
0.81
|
|
58
|
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART.
|
Ann Nutr Metab
|
2006
|
0.80
|
|
59
|
Update on different aspects of HCV variability: focus on NS5B polymerase.
|
BMC Infect Dis
|
2014
|
0.80
|
|
60
|
Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
|
BMC Infect Dis
|
2014
|
0.79
|
|
61
|
The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.
|
J Nephrol
|
2015
|
0.79
|
|
62
|
The impact of gender and anchor drugs on TDF renal toxicity.
|
J Acquir Immune Defic Syndr
|
2010
|
0.79
|
|
63
|
Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?
|
J Clin Psychopharmacol
|
2002
|
0.79
|
|
64
|
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
|
Antivir Ther
|
2007
|
0.78
|
|
65
|
The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
|
Antivir Ther
|
2006
|
0.78
|
|
66
|
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort.
|
BMC Infect Dis
|
2013
|
0.78
|
|
67
|
Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.
|
Clin Infect Dis
|
2006
|
0.78
|
|
68
|
Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy?
|
BMC Infect Dis
|
2014
|
0.77
|
|
69
|
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
|
Medicine (Baltimore)
|
2016
|
0.77
|
|
70
|
Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules.
|
Curr HIV Res
|
2011
|
0.77
|
|
71
|
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients.
|
J Acquir Immune Defic Syndr
|
2007
|
0.77
|
|
72
|
Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
|
Neuropsychobiology
|
2002
|
0.76
|
|
73
|
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.
|
AIDS
|
2015
|
0.76
|
|
74
|
Bcl-2 expression is moderately correlated with long-term variability of CD4 T-cell increase under successful highly active antiretroviral therapy.
|
AIDS
|
2003
|
0.76
|
|
75
|
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.
|
New Microbiol
|
2014
|
0.76
|
|
76
|
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.
|
J Acquir Immune Defic Syndr
|
2004
|
0.76
|
|
77
|
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report.
|
J Med Case Rep
|
2007
|
0.76
|
|
78
|
Immunity to human immunodeficiency virus (HIV) infection.
|
Clin Dev Immunol
|
2012
|
0.76
|
|
79
|
Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of rebound.
|
J Infect Dis
|
2002
|
0.75
|
|
80
|
Challenging clinical cases in HCV infection.
|
BMC Infect Dis
|
2014
|
0.75
|
|
81
|
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy.
|
BMC Infect Dis
|
2014
|
0.75
|
|
82
|
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.
|
AIDS Rev
|
2005
|
0.75
|
|
83
|
[New strategies and new drugs in the salvage therapy for HIV infection].
|
Med Clin (Barc)
|
2002
|
0.75
|
|
84
|
Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapy.
|
New Microbiol
|
2012
|
0.75
|
|
85
|
The role of Gram-negative bacteria in skin and soft tissue infections.
|
Curr Opin Infect Dis
|
2022
|
0.75
|
|
86
|
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
|
J Antimicrob Chemother
|
2003
|
0.75
|
|
87
|
[A population-based database to study malignancies in HIV-infected patients in the Local Health Unit of Brescia (Northern Italy), period 1999-2009].
|
Epidemiol Prev
|
2013
|
0.75
|
|
88
|
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.
|
New Microbiol
|
2013
|
0.75
|
|
89
|
[The novel non-A, non-E hepatitis viruses and their pathogenic effect].
|
Med Clin (Barc)
|
2004
|
0.75
|
|
90
|
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide.
|
AIDS
|
2007
|
0.75
|
|
91
|
The disagreement among methods to evaluate glomerular filtration rate in HIV-infected patients naive to antiretroviral therapy.
|
AIDS Res Hum Retroviruses
|
2011
|
0.75
|
|
92
|
For timing of HAART is less more? CD4+/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features.
|
New Microbiol
|
2014
|
0.75
|
|
93
|
[Usefulness of pharmacokinetics in the management of antiretroviral therapy].
|
Med Clin (Barc)
|
2005
|
0.75
|
|
94
|
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations.
|
J Acquir Immune Defic Syndr
|
2004
|
0.75
|
|
95
|
HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure.
|
Infect Genet Evol
|
2013
|
0.75
|